ceftaroline x mrsa

Ceftaroline was approved by the Food and Drug Administration (FDA) on November 1, 2010 for adults with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by susceptible bacteria. On May 31, 2016, the FDA extended the approval to include children 2 months of age and older.^[1,2] Ceftaroline offers the advantage of a broad spectrum of activity, with efficacy against SSSI caused by methicillin-resistant Staph. aureus (MRSA) and other difficult to treat infections, in addition to a relatively mild adverse effect profile. A number of recent papers describe the studies that were done to support the FDA indication for use in infants, children, and adolescents